Neurologic Clinics
Volume 25, Issue 4 , Pages 1089-1109, November 2007

Anaplastic Oligodendroglioma and Oligoastrocytoma

Neuro-Oncology Unit, Daniel den Hoed Cancer Clinic/Erasmus University Medical Center, PO Box 5201, 3008AE Rotterdam, the Netherlands

Until approximately 15 years ago, the diagnosis of an oligodendroglioma (OD) was merely as a pathologic entity. The only clinical relevant meaning of this histologic diagnosis was the observation that the prognosis of OD was in general better than that of astrocytic tumors of similar grade. This changed with the recognition of the marked sensitivity to PCV chemotherapy of these tumors, although the best timing of chemotherapy still is unclear. Observations have led to the current tendency to consider 1p/19q loss low-grade and anaplastic oligodendroglioma a separate biologic entity, at least within clinical trials, since they have a much better outcome.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0733-8619(07)00087-4

doi:10.1016/j.ncl.2007.07.013

Neurologic Clinics
Volume 25, Issue 4 , Pages 1089-1109, November 2007